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COMMENTARY
Preventing end-stage renal disease: The potential impact of
screening and intervention in developing countries
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another of renal replacement therapy (RRT) [1]. Ninety
EDITORS’ NOTE percent of them live in the developed countries, or, as
The editorial commentary by Schieppati, Perico, and they are defined by the World Bank, high-income coun-
Remuzzi is devoted to one of the most important tries, where the average gross income is in excess of
issues in the field of nephrology, namely, the preven- $10,000 per capita.
tion of end-stage renal disease (ESRD). These au- There is a clear, direct relationship between gross na-
thors, as well as several other groups, have demon- tional product (GNP) and availability of RRT. Dialysis
strated the efficacy of a variety of pharmacologic and treatment absorbs 0.7 to 1.8% of the health care budget
non-pharmacologic interventions in decreasing pro- in European countries, while the dialysis population rep-
teinuria and high blood pressure, thereby obtaining resents 0.02 to 0.05% of the whole population [2]. In the
a marked slowing of renal disease progression and Eastern European countries, the so-called former Soviet
even its full arrest in the most favorable cases. Al- block, the prevalence rate of RRT is half or less than in
though such highly satisfactory results in terms of countries of the European Union; also the average GNP
renal disease and prevention are largely true for pa- in those countries is half or less than in Western Europe
tients in Western world countries, the majority of pa- [3, 4]. It is hard to believe that the epidemiology of renal
tients in the developing countries of the world do not diseases differs that much in the two areas of Europe.
yet benefit from it. Simply put, RRT is so costly that there is minimal prob-
ability for the vast majority of the world’s population toBecause of the exceptional importance of the mea-
take advantage of it.sures proposed by Schieppati, Perico, and Remuzzi,
The future perspectives are gloomy. A forecast analy-aimed at changing the present situation by a global
sis predicts that in 10 years there will be 2 million peopleapproach, we have taken the exceptional decision to
on RRT, and even developed countries will be strainedpublish this commentary in our two journals simulta-
by the rising costs [1].neously.
The major causes of ESRD in North America and in
Tilman B. Dru¨eke
many developed countries are diabetes and hyperten-
Editor-in-Chief
sion, which together account for almost 60% of dialysis
Nephology Dialysis Transplantation
patients [5]. On the other hand, high blood pressure and
Saulo Klahr diabetes mellitus contribute in a significant way to the
Editor-in-Chief rising burden of global morbidity and mortality associ-
Kidney International ated with cardiovascular diseases. The prevalence of both
conditions is rising significantly not only in developed
countries, but also in developing ones [6]. The shift fromThere are about 1 million people in the world that
an active life as farmers to a less-active lifestyle associ-are alive just because they have access to one form or
ated with urbanization, and an increased consumption
of sugar and fat, are among the factors responsible for
Key words: end-stage renal disease, renal replacement therapy, angio- the rise of obesity and related diseases [6].
tensin-converting enzyme inhibitors. Data gathered from clinical studies and randomized
trials in developed countries have demonstrated that pre-Received for publication December 9, 2002
Accepted for publication December 9, 2002 vention of progression of cardiovascular and renal dis-
eases is feasible. Reduction of high blood pressure and 2003 by the International Society of Nephrology
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proteinuria with angiotensin-converting enzyme inhibi- fessionals should receive rigorous training to allow them
to return to their countries and start the program.tors or angiotensin receptor blockers, control of blood
glucose and lipids, along with non-pharmacologic mea- The implementation of such an ambitious program
cannot be realized without the involvement of interna-sures, such as smoking cessation, physical activity, and
body weight control, offer an undisputable protection tional agencies such as the World Health Organization
(WHO) and the World Bank (WB). Actually, during theagainst cardiovascular and renal diseases [7].
The Commission for the Global Advancement of Ne- last year, the issues of the global renal and cardiovascu-
lar disease burden have been the objects of formal pre-phrology (COMGAN) of the International Society of
Nephrology, established in 1993, has focused its attention sentations at WHO and WB, where there has been keen
interest and appreciation.on education and training of staff in developing countries
and has developed the Renal Sister Center Program. A At the local level it is important to establish contacts
with national scientific societies. Such contacts are indis-COMGAN Research Committee has been established
with the general aim to provide opportunities for re- pensable tools for the health authorities and the national
governments.search in emerging countries in which Western expertise
can be applied to local problems. Since ultimately the realization of the program re-
quires equipment and medicinal products, partnershipWe believe that, with some effort, prevention of the
progression of renal disease with the combination of phar- with pharmaceutical industry is of paramount impor-
tance. Diagnostic devices and drugs for treating hyper-macologic and non-pharmacologic approaches can be
exported to less developed countries. Screening pro- tension, high blood cholesterol, and glucose should be
donated or at least offered at affordable prices to lowgrams can be implemented with simple, cheap, and reli-
able tests, such as measurement of body weight, blood income countries where prevention programs are imple-
mented. The pharmaceutical industry has produced manypressure, blood glucose, and dipstick urinalysis for pro-
tein. Examples already exist. In India [8] and Bolivia [9] drugs that have benefited the human species. However,
this has also been a most profitable enterprise. As wea large number of people can already be screened with
affordable means. have written elsewhere, “. . . the industry’s impact on
public health is so great, and the subsidies and protec-The impact on renal and cardiovascular morbidity and
mortality of relatively simple measures, such as blood tions offered by governments so generous, that the indus-
try should consider its social responsibilities and not justpressure reduction, good glycemic control, and smoking
cessation, is great and significant at any targeted level its profits” [12]. We propose that a very small fraction
of industry revenue be used to provide medicines for areached [10]. Moreover, quite soon drug patents should
expire for antihypertensive agents that have specific pro- prevention program of renal and cardiovascular diseases
in poor countries.tective effects against both renal and cardiovascular dis-
eases, such as angiotensin-converting enzyme inhibitors, In particular, we invite those companies that have
developed drugs which have proven in clinical trials tomaking it feasible to implement more vigorous preven-
tive programs even in less favorable settings. Indeed, a be specifically cardio- and renoprotective to support such
programs to assist less developed countries.pilot program has been conducted in an Australian Ab-
original community [11]. A systematic treatment program, This is a unique opportunity for renal physicians and
professionals from rich countries to offer their help tocombining blood pressure reduction and improved glu-
cose and lipid control with health education, was associ- develop simple but effective prevention programs in parts
of the world where there is very little to no chance forated with an improvement in clinical profile and mortality.
This is exactly the real mission of the COMGAN Re- those affected by kidney disease.
Finally, as it was simply stated in a recent editorial insearch Committee: the translation of the results of clini-
cal research into clinical practice on a global basis, rather the Lancet, the magic bullet that is indispensable to cure
most of the problems is money [13]. By analogy with thethan only in those parts of the world where the data
have been obtained. Global Fund to Fight AIDS, Tuberculosis, and Malaria,
the International Society of Nephrology (COMGAN)To this purpose, multiple actions have to be taken.
Education and training of health professionals is the first should promote the establishment of a Global Fund to
Fight Renal Diseases. It is true that money is hard topriority. A comprehensive training program for physi-
cians and nurses should be established and carried on find and when available is always less than needed. How-
ever, the value of the investment in renal prevention pro-in selected institutions in developed countries, like a sort
of “global nephrology fellowship.” The program should grams is astonishing. As compared to other health
scourges, treatment of progressive nephropathies is rela-give priority to topics such as epidemiology, develop-
ment of screening and treatment protocols, and data tively inexpensive and may save a lot of money, or—in
poor countries—something much more precious: life.handling. It is important to underscore that health pro-
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